Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for GVHD Prophylaxis (GRAVITAS-119)
NCT03320642Phase 1Terminated
- Sponsor
- Incyte
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of itacitinib in graft-versus-host disease (GVHD), sponsored by Incyte. Primary endpoint: Proportion of participants with hematologic recovery at 28 days. Started Feb 2018; status: terminated.
02
Drugs
itacitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03320642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320642.